Search results: (10000)
News ASH 2020: Efficacy and Safety of Emicizumab in Long-term Follow-up
At the virtual meeting of the American Society of Hematology (ASH) in December 2020, the latest data concerning the long-term follow-up of participants in the HAVEN 1−4 clinical trials with emicizumab were published.
News What does the analysis of the CHESS PAEDs study say about the relationship between physical activity and the frequency of bleeding events in children with hemophilia A?
Currently, there is limited published data addressing the relationship between physical activity and the occurrence of bleeding events in children with hemophilia A. To gain insights into this topic in real-world practice, data from the CHESS PAEDs study were analyzed. The results were presented in the poster section of the virtual congress of the International Society on Thrombosis and Haemostasis (ISTH).
News ASH 2020: Two Real-World Perspectives on Experiences with Emicizumab Prophylaxis
Data presented at the ASH 2020 congress bring interesting insights regarding the administration of emicizumab in real clinical practice. It provides comprehensive information on the relatively high number of individuals treated with emicizumab in relation to persistence on treatment and adherence to it. Data from the EUHASS registry confirms the good safety profile of this treatment even in regular clinical practice across Europe.
News Cardiovascular Interventions with Continued Therapy with Dabigatran − Insights from the GLORIA-AF Study
An analysis using data from an international registry of patients with newly diagnosed atrial fibrillation evaluated the safety and efficacy of continued therapy with dabigatran during cardioversion or atrial fibrillation ablation, pacemaker implantation, and coronary angiography with possible stent implantation.
News The Importance of Adequate Protein Intake in Critical Patients – Analysis of Data from an International Study
Adequate protein intake is a necessary part of care for critically ill patients and mitigates catabolic reactions associated with severe illness or injury. The benefits of proper determination and adherence to protein intake, however, have not been sufficiently assessed in detail. Therefore, this topic was the focus of a work analyzing data from an international observational multicenter study published in the Journal of Parenteral and Enteral Nutrition.
News Efficacy of Baricitinib in Long-term Therapy of Rheumatoid Arthritis
Baricitinib selectively and reversibly inhibits Janus kinases JAK1 and JAK2 and is used in the treatment of adults with active rheumatoid arthritis (RA). Its safety during long-term administration has already been demonstrated by previous analyses, with treatment durations of up to 7 years. Equally important is the long-term efficacy of this drug, which was the focus of work presented in June of this year at the annual European rheumatology congress EULAR 2020.
News ESC 2022: What Do the Latest Real-World Data Say About the Use of DOACs in Atrial Fibrillation?
Why are real-world data so important? What new insights can they provide about established medications, such as direct oral anticoagulants (DOACs), in the treatment of patients with atrial fibrillation (AF)? What makes the GLORIA-AF registry unique, and what insights have been published from it this year? These topics were also discussed at the ESC 2022 Congress.
News Factors Predicting Longer Survival in Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil
A recently published non-interventional analysis evaluated overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) with favorable prognostic factors before initiating treatment with trifluridine/tipiracil compared to patients with unfavorable factors. It also identified which specific prognostic factors are favorable in terms of therapy effectiveness.
News Comparison of Cardiovascular Effects of Sitagliptin and Empagliflozin
Cardiovascular (CV) diseases remain the leading cause of death among patients with type 2 diabetes (T2D). Reducing the incidence of macrovascular CV events in diabetics requires more than just glycemic control alongside all other present CV risk factors. New antidiabetic drugs represent a very promising group of medications with a favorable safety profile, aiding in reducing the risk of CV complications.
News Impact of Adequate Protein Intake on Morbidity and Mortality in Critically Ill Patients
The following text provides a summary of findings from clinical studies in the field of nutritional therapy for critically ill patients and its impact on protein metabolism and patient outcomes.
News Cannabidiol as a way to reduce anxiety in patients with Parkinson's disease?
A recent study by Brazilian authors examined the effects of cannabidiol on tremors and anxiety in patients with Parkinson's disease. Could it represent a promising modality in this indication?
News Is long-term treatment with ixekizumab sufficiently safe?
Psoriasis is a chronic inflammatory disease whose manifestations require long-term treatment. A poster presented at last year's European Academy of Dermatology and Venereology (EADV) congress summarizes ixekizumab safety data from monitoring lasting up to 5 years, based on nearly 18,000 patient-years (PY) in the treatment of this disease.
News European Registry of Patients with Alpha-1 Antitrypsin Deficiency EARCO Enrolls Patients
Insufficient identification of patients with alpha-1 antitrypsin deficiency (AATD) and a lack of knowledge about this disease have led to the launch of the European Registry EARCO, which is currently enrolling patients. The aim is to better describe the pathophysiology of the disease and the prognosis of these patients, and to create a validated prognostic tool to aid clinical decision-making.
News HAE in the Otolaryngologist's Office: How to Handle a Laryngeal Attack?
Hereditary angioedema (HAE) can be encountered in emergency rooms and specialist offices. Patients with this rare disorder are often misdiagnosed with a more common condition, and they may learn their correct diagnosis only after many years. This is because HAE manifests with a combination of symptoms that are typical of various other diseases. What should pediatricians, otorhinolaryngologists, and gastroenterologists be aware of? Providing better understanding of HAE symptoms from different specializations' perspectives and emphasizing the importance of interdisciplinary collaboration for accurate diagnosis and patient care was the focus of a professional webinar we have summarized for you.
News Safety and efficacy of dabigatran and other NOACs compared with warfarin in patients with atrial fibrillation – results of a large long-term prospective study
Anticoagulant therapy is key in the prevention of strokes in patients with atrial fibrillation. Until the introduction of new oral anticoagulants (NOACs), warfarin was the first-choice drug for these patients, but unlike NOACs, it requires careful dose titration and effect monitoring. The safety and benefits of using various anticoagulants were examined in the study below.
News Turoctocog Alfa Pegol with Extended Half-Life in the Treatment of Severe Hemophilia A
GlycoPEGylated recombinant factor VIII (rFVIII) with an extended half-life, turoctocog alfa pegol, has demonstrated prophylactic efficacy in patients with severe hemophilia A aged over 12. This product is administered only once every 4 days. In addition to a comparable reduction in the annual bleed rate to standard FVIII prophylaxis products, it has also shown sufficient efficacy in bleeding treatment and a minimal risk of inhibitory antibody formation.
News Intravenous Fixed Combination NEPA in the Prevention of Chemotherapy-Induced Vomiting
Summary data from several studies were used by the authors of the following analysis to evaluate the efficacy of the intravenous and oral forms of the fixed combination NEPA (netupitant/fosnetupitant + palonosetron) administered with dexamethasone in preventing chemotherapy-induced vomiting based on cisplatin or anthracycline and cyclophosphamide (AC).
News How does empagliflozin perform in older type 2 diabetics compared to liraglutide and sitagliptin in terms of HHF and MACE risks?
Last fall, a study was published in JAMA Network Open, focusing on older patients with type 2 diabetes mellitus (DM2), examining the cardiovascular risk impact when treated with empagliflozin, liraglutide, or sitagliptin. Currently, there is limited evidence comparing the effectiveness of various glucose-lowering agents intended for second-line treatment in DM2 patients undergoing routine care, who have a broad spectrum of cardiorenal risks.
News Safety and Efficacy of Long-term Tofacitinib Therapy in Patients with Active Psoriatic Arthritis – Interim Results of the OPAL Balance Study
Tofacitinib is a potent selective inhibitor of the Janus kinase (JAK) family indicated for the treatment of active psoriatic arthritis in adult patients. The efficacy and safety of tofacitinib in this population have been verified for 6 and 12 months through clinical studies OPAL. A study published in 2020 presents interim results of the extended phase of these studies, evaluating its efficacy and safety in the long term.
News Heart Failure in the Light of New ESC Guidelines
Dear Doctor, The Czech Society of Internal Medicine of ČLS JEP invites you to watch the symposium, which will take place on Wednesday, November 3rd, at 5 PM.
You can find more information in the invitation attached below.
You can find more information in the invitation attached below.
News Patient with Moderate Hemophilia A and Development of FVIII Inhibitor in Old Age and Atrial Fibrillation − Interactive Case Study
MUDr. Petr Smejkal, Ph.D., from the Department of Clinical Hematology, FN Brno, has prepared a case study for you of a patient born in 1941, diagnosed with hemophilia A at around 10 years of age. In 2013, he underwent surgery for right carotid stenosis with pdFVIII substitution and was started on acetylsalicylic acid.
Two weeks after discharge, subcutaneous and muscle bleeding was recognized, leading to the development of an FVIII inhibitor (high responder) with FVIII levels < 1%. Severe muscle bleeds continued approximately once every 2 months. Prophylactic treatments progressively included aPCC, pdFVIII, and emicizumab.
The patient also presents with cardiovascular comorbidities: atrial fibrillation (AF) accompanied by its dilatation, diastolic heart failure, and hypertension. In 2021, he also contracted COVID-19, requiring hospitalization.
News Boy with Hemophilia A with Inhibitor − Case Study with Voting
Presented by: Assoc. Prof. MUDr. Jan Blatný, Ph.D., Department of Pediatric Hematology, University Hospital Brno
News Improvement of Executive Functions in Therapy of Dravet Syndrome with Fenfluramine in Preschool Children
Dravet syndrome is a rare genetic progressive epileptic encephalopathy that is usually accompanied by intellectual and behavioral disorders. Many children with this syndrome also struggle with deficits in executive functions. An analysis recently published in the journal Epilepsy & Behavior assessed the impact of fenfluramine therapy on executive functions in preschool children with this condition.
News Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy
New molecules in hemophilia therapy have raised many questions, including regarding the significance and need for immune tolerance induction (ITI). Interesting conclusions from the FIT (Future of Immunotolerance Treatment) expert panel discussion on the future of ITI, its form, and indication were published in July 2019.
News Population Pharmacokinetics of Perioperative Administration of Coagulation Factors in Patients with von Willebrand Disease
For many patients with von Willebrand disease, the administration of coagulation factors is an important part of perioperative care. Due to the absence of pharmacokinetic models, predicting therapeutic levels is challenging, leading to a higher risk of bleeding or thrombotic events. To create the missing model, a long-term study was conducted by Dutch authors.